Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies
Luisa Chiapparini
Annals of Neurology, 2013
View PDFchevron_right
Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Fabrizio Piazza
Frontiers in Neurology
View PDFchevron_right
Anti-Aβ autoantibodies in the CSF of a patient with CAA-related inflammation: a case report
Laura Brighina
Neurology, 2011
View PDFchevron_right
Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications
Pierre Aucouturier
Frontiers in Immunology
View PDFchevron_right
Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression
Cristiana Barbati
Autoimmunity Reviews, 2010
View PDFchevron_right
Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients
Hayrettin Tumani
PLoS ONE, 2013
View PDFchevron_right
Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-β(1-42) deposition
Nikhil Thaker
Journal of Alzheimer's disease : JAD, 2011
View PDFchevron_right
Beta-amyloid auto-antibodies are reduced in Alzheimer's disease
Dwight German
Journal of Neuroimmunology, 2014
View PDFchevron_right
Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation
Milica Kramberger
Journal of Alzheimer's disease : JAD, 2016
View PDFchevron_right
Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide
Yansheng Du
Biological Psychiatry, 2005
View PDFchevron_right
Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy
Roxana Carare
Acta neuropathologica, 2014
View PDFchevron_right
Immune complexes of auto-antibodies against Aβ1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients
Andreas Henkel
Molecular Psychiatry, 2007
View PDFchevron_right
Quantification of amyloid-beta 40 in cerebrospinal fluid
Robert Veerhuis
Journal of Immunological Methods, 2009
View PDFchevron_right
Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of -Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis
Katja Herges
Science Translational Medicine, 2012
View PDFchevron_right
Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease
Gjermund Henriksen
Neurosci Lett, 2009
View PDFchevron_right
Intracerebroventricular amyloid- antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice
Lisa Shafer
Proceedings of the National Academy of Sciences, 2009
View PDFchevron_right
Cerebrospinal Fluid Aβ42 Levels: When Physiological Become Pathological State
Giuseppe Sancesario
CNS Neuroscience & Therapeutics, 2015
View PDFchevron_right
Cerebrospinal fluid amyloid β40is decreased in cerebral amyloid angiopathy
Peter van Domburg
Annals of Neurology, 2009
View PDFchevron_right
Reduced Levels of Cerebrospinal Fluid/Plasma Aβ40 as an Early Biomarker for Cerebral Amyloid Angiopathy in RTg-DI Rats
Helene Benveniste
International Journal of Molecular Sciences, 2020
View PDFchevron_right
Specific reactivity of mild/severe Alzheimer’s disease patient’s sera to antibody against Aβ1-40 epitope 17-21
Funda Hatip
Acta Neurologica Scandinavica, 2007
View PDFchevron_right
Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease
Toshiki Mizuno
PloS one, 2017
View PDFchevron_right
Decreased -amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
Manuela Neumann
Neurology, 2000
View PDFchevron_right
Neuroinflammation in Plaque and Vascular β-Amyloid Disorders: Clinical and Therapeutic Implications
Robert Veerhuis
Neurodegenerative Diseases, 2008
View PDFchevron_right
Distinct Patterns of Antiamyloid-β Antibodies in Typical and Atypical Alzheimer Disease
Olivier Colliot
Archives of Neurology, 2012
View PDFchevron_right
The Role of CSF Biomarkers in Discriminating Between Cerebral Amyloid Angiopathy and Alzheimer’s Disease Patients: Systematic Review of Clinical Studies
Caspian Journal of Neurological Sciences (CJNS)
Caspian Journal of Neurological Sciences, 2024
View PDFchevron_right
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)
Kewei Chen
Alzheimer's research & therapy, 2018
View PDFchevron_right
The Neuroinflammatory Response in Plaques and Amyloid Angiopathy in Alzheimers Disease: Therapeutic Implications
Piet Eikelenboom
Current Drug Target -CNS & Neurological Disorders, 2005
View PDFchevron_right
Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity
YeQing Pi
Brain : a journal of neurology, 2015
View PDFchevron_right
Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration
Jerzy Wegiel
Acta Neuropathologica, 2007
View PDFchevron_right
Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
Raymond S Turner
Frontiers in Neurology, 2022
View PDFchevron_right
Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain
Seth Love
Brain, 2008
View PDFchevron_right
Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization
Delphine Boche
Brain, 2013
View PDFchevron_right